Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Zimmer Biomet Holdings    ZBH

ZIMMER BIOMET HOLDINGS

(ZBH)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Zimmer Biomet : to Present at 2020 Evercore ISI HealthCONx Conference and Piper Sandler 32nd Annual Virtual Healthcare Conference

11/18/2020 | 09:44am EST

WARSAW - Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal care, today announced that President and CEO Bryan Hanson and Executive Vice President and CFO Suky Upadhyay will be presenting at the 2020 Evercore ISI HealthCONx Conference on Tuesday, December 1, 2020, at 10:30 a.m. Eastern Time.

Additionally, Executive Vice President and CFO Suky Upadhyay will be presenting at the Piper Sandler 32nd Annual Virtual Healthcare ConferenceWednesday, December 2, 2020, at 11:00 a.m. Eastern Time.

Live webcasts of the presentations can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com. The webcasts will be archived for replay following the conference.

About the Company

Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer Biomet is a global leader in musculoskeletal healthcare. We design, manufacture and market orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants and related surgical products.

We collaborate with healthcare professionals around the globe to advance the pace of innovation. Our products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Together with healthcare professionals, we help millions of people live better lives.

Contact:

Meredith Weissman

Tel: 703-346-3127

Email: meredith.weissman@zimmerbiomet.com

(C) 2020 Electronic News Publishing, source ENP Newswire

All news about ZIMMER BIOMET HOLDINGS
01/11ZIMMER BIOMET : Announces Webcast and Conference Call of Fourth Quarter 2020 Fin..
AQ
01/08ZIMMER BIOMET : Announces Webcast and Conference Call of Fourth Quarter 2020 Fin..
PR
01/07ZIMMER BIOMET : UBS Adjusts Price Target on Zimmer Biomet Holdings to $182 From ..
MT
01/04ZIMMER BIOMET : Guggenheim Upgrades Zimmer Biomet Holdings to Buy From Neutral; ..
MT
01/04ZIMMER BIOMET : Evercore ISI Upgrades Zimmer Biomet Holdings to Outperform From ..
MT
2020Stocks End Lower After Push for Higher Stimulus Payments Stalls in Senate
MT
2020ZIMMER BIOMET : Argus Adjusts Zimmer Biomet Holdings PT to $170 From $160, Maint..
MT
2020ZIMMER BIOMET HOLDINGS : Ex-dividend day for
FA
2020UPDATE : Zimmer Biomet Picked as Top 2021 Healthcare Stock Pick by Needham; Pric..
MT
2020ZIMMER BIOMET : Picked as Top 2021 Healthcare Stock Pick by Needham; Price Targe..
MT
More news
Financials (USD)
Sales 2020 7 040 M - -
Net income 2020 -175 M - -
Net Debt 2020 6 852 M - -
P/E ratio 2020 -183x
Yield 2020 0,61%
Capitalization 33 189 M 33 189 M -
EV / Sales 2020 5,69x
EV / Sales 2021 4,76x
Nbr of Employees 19 900
Free-Float 66,5%
Chart ZIMMER BIOMET HOLDINGS
Duration : Period :
Zimmer Biomet Holdings Technical Analysis Chart | ZBH | US98956P1021 | MarketScreener
Technical analysis trends ZIMMER BIOMET HOLDINGS
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 30
Average target price 167,21 $
Last Close Price 160,12 $
Spread / Highest target 20,5%
Spread / Average Target 4,43%
Spread / Lowest Target -33,8%
EPS Revisions
Managers and Directors
NameTitle
Bryan C. Hanson President, Chief Executive Officer & Director
Larry C. Glasscock Non-Executive Chairman
Kenneth R. Tripp Senior VP-Global Operations & Logistics
Suketu P. Upadhyay Executive VP, Chief Financial & Accounting Officer
David J. Kunz VP-Global Quality, Clinical & Regulatory Affairs
Sector and Competitors
1st jan.Capitalization (M$)
ZIMMER BIOMET HOLDINGS3.91%33 189
ABBOTT LABORATORIES1.65%190 701
MEDTRONIC PLC-0.28%157 229
BECTON, DICKINSON AND COMPANY4.60%76 127
HOYA CORPORATION-2.28%50 041
ALIGN TECHNOLOGY, INC.6.15%44 726